Main Article Content

Roberto Castelli
(*) Corresponding Author:


Background: Splenic marginal zone lymphoma (SMZL) is a chronic B-cell lymphoproliferative disorder, comprising less than 2% of non-Hodgkin’s lymphomas, and affecting mainly middle-aged and elderly patients with a median survival of >10 years. The typical clinical features of SMZL include splenomegaly. Treatment should be patient-tailored and can range from a ‘watchful waiting’ approach for asymptomatic patients without cytopenias to surgery, localized radiation therapy or immuno/chemotherapies. Recently, the combination of Rituximab and Bendamustine (R-Benda) has been defined as highly active in patients with follicular lymphomas, but little is known about the efficacy of R-Benda in SMZL.  

Aim of the study: The purpose of this retrospective study was to report our experience on the efficacy of R-Benda as first line treatment in 23 consecutive elderly SMZL patients. 

Results: All patients had a complete resolution of splenomegaly along with restoration of their blood counts. Nineteen patients (83%) achieved a complete response (CR) to therapy; three patients (13%) achieved a partial response (PR).Ten patients (43%) obtained molecular remission. Toxicities were mild and mainly haematological and result in dose reductions for fourteen patients. 

Conclusions: Our data suggest a high activity and good tolerance of R-Benda, despite dose reduction due to potential toxicity.

Downloads month by month


Download data is not yet available.

Article Details

Author Biography

Roberto Castelli, University of Milan




1. Kahl, B. and Yang, D. Marginal zone lymphomas: management of nodal, splenic, and MALT NHL. Haematology 2008 Am Soc Haematology EducProgram: 359–364.
2. Zucca, E ,Dreyling, M. and Grp, E.G.W. Gastric marginal zone lymphoma of malt type: esmo clinical practice guidelines for diagnosis, treatment and follow-up. Annals of Oncology2010 21: v175-v176.
3. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84:1361–1392.
4. Troussard, X., Valensi, F., Duchayne, E., Garand, R., Felman, P., Tulliez, M. et al. Splenic lymphoma with villous lymphocytes: clinical presentation, biology and prognostic factors in a series of 100 patients. GroupeFrancaisd’HematologieCellulaire (GFHC). Br J Haematol 1996 93: 731–736.
5. Castelli R, Wu MA, Arquati M, Zanichelli A, Suffritti C, Rossi D, Cicardi M. High prevalence of splenic marginal zone lymphoma among patients with acquired C1 inhibitor deficiency. Br J Haematology. 2016 Jan 5. doi: 10.1111/bjh.13908. [Epub ahead of print]
6. Berger, F, Felman, P, Thieblemont, C., Pradier, T., Baseggio, L., Bryon, P. et al. Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patients. Blood 200095: 1950–1956.
7. Cervetti, G., Mechelli, S., Riccioni, R., Galimberti, S., Caracciolo, F. and Petrini, M. (2005) High efficacy of rituximab in indolent HCV-related lymphoproliferative disorders associated with systemic autoimmunediseases. ClinExpRheumatol2005 23: 877–880.
8. Zucca E, Conconi A, Laszlo D et al Addition ofrituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis if the IELSG-19 randomized study. J ClinOncol (2013) 31:565–72
9. Ben Simon GJ, Cheung N,McKelvie P et al (2006) Oral clorambucil for extranodal, marginal zone, B-cell lymphoma if mucosa-associatedlymphoid tissue of the orbit. Ophthalmology 113:1209–13
10. TrochM,Kiesewetter B, Willenbacher Wet al Rituximab plus subcutaneous cladribine in patients with extranodal marginal zone Bcelllymphoma of mucosa-associated lymphoid tissue: a phase II .Haematologica 2013: 98:264–8
11. Kalpadakis, C., Pangalis, G, Dimopoulou, M., Vassilakopoulos, T., Kyrtsonis, M., Korkolopoulou, P. et al. Rituximab monotherapy is highly effective in splenic marginal zone lymphoma. HematolOncol 2007 l25:127–131
12. EnnishiD, Yokoyama M, Mishima Y et al Rituximab plus CHOP as an initial chemotherapy for patients with disseminated MALT lymphoma. Leuk Lymphoma 2007. 48:2241–3.
13. Derksen PWB, Langerak AW, Kerkhof E, et al. Comparison ofdifferent polymerase chain reaction-based approaches for clonalityassessment of immunoglobulin heavy-chain gene rearrangementsin B-cell neoplasia. Mod Pathol 1999; 12: 794–805.
14. Arcaini, L., Lazzarino, M., Colombo, N., Burcheri, S., Boveri, E., Paulli, M. et al. (2006) Splenicmarginal zone lymphoma: a prognostic model for clinical use. Blood 2006 107: 4643–4649
15. Arcaini, L. and Paulli, M. (2010) Splenic marginal zone lymphoma: hydra with many heads?Haematologica95: 534–537
16. Franco V, Florena AM, Stella M, et al. Splenectomy influencesbone marrow infiltration in patients with splenic marginal zone cell lymphoma with or without villous lymphocytes. Cancer2001; 91: 294–301.
17. Bennett, M. and Schechter, G. Treatment of splenic marginal zone lymphoma: splenectomy versus rituximab. SeminHematol(2010) 47: 143–147.
18. Troussard X, Valensi F, Duchayne E, et al. Splenic lymphoma with villous lymphocytes. Clinical presentation, biology andprognostic factors in a series of 100 patients. Br J Haematol 1996; 93: 731–736.
19. Catovsky D, Matutes E. Splenic lymphoma with circulating villous lymphocytes/ splenic marginal-zone lymphoma. SeminHematol 1999; 36: 148–154
20. Lefrere F, Hermine O, Belanger C, et al. Fludarabine: an effective treatment in patients with splenic lymphoma with villous lymphocytes. Leukemia 2000; 14: 573–575.
21. Pangalis GA, Vassilakopoulos TP, KalpadakisCh, et al. Treatment of indolent lymphomas from watch and wait to high dose therapy. Hematology 2005; 1: 6–9.
22. Riccioni R, Caracciolo F, Galimberti S, Cecconi N, Petrini M. Low dose 2-CdA schedule activity in splenicmarginal zone lymphomas. HematolOncol 2003; 21: 163–168.
23. Lefrerre F, Hermine O, Francois S. et al. Lack of efficacy of 2-chlorodeoxyadenoside in the treatment of splenic lymphoma with villous lymphocytes. Leuk Lymphoma 2000; 40: 113– 117
24. Bolam S, Orchard J, Oscier D. Fludarabine is effective in the treatment of splenic lymphoma with villous lymphocytes. Br J Haematol 1997; 99: 158–161
25. Damaj G, Gressin R, Bouabdallah K, Cartron G, Choufi B, Gyan E, et al. Results from a prospective, open-label, phase II trial of Bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial. J ClinOncol 2013;31:104–10)
26. Rummel MJ, Gregory SA. Bendamustine's emerging role in the management of lymphoid malignancies. SeminHematol 2011;48 Suppl 1: S24–36);
27. Chacar C, Jabbour E, Ravandi F, Borthakur G, Kadia T, Estrov Z, et al. Phase I-II study of Bendamustine in patients with acute leukemia and high risk myelodysplastic syndrome. Clin Lymphoma Myeloma Leuk 2012;12:197–200
28. Kahl, B., Bartlett, N., Leonard, J., Chen, L., Ganjoo, K., Williams, M. et al. (2010a) Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a multicenter study. Cancer 116: 106–114.
29. Kiesewetter B, Mayerhoefer ME, Lukas J, Zielinski CC, Müllauer L, Raderer M . Rituximab plus Bendamustine is active in pretreated patients with extragastric marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma Ann Hematol. 2014 Feb;93(2):249-53).